High-dose chemotherapy with autologous bone marrow transplantation in patients with refractory ovarian cancer

European Journal of Cancer and Clinical Oncology

Volumn 25, Issue 4, 1989, Pages 645-649

  Mulder, Paula O M ^a   Willemse, Pax H B ^a   Aalders, Jan G ^a   de Vries, Elisabeth G E ^a   Sleijfer, Dirk Th ^a   Smit Sibinga, Cees Th ^a   Mulder, Nanno H ^a  

^a CENTRAL LABORATORY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; ETOPOSIDE; MESNA;

ADULT; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; OVARY CANCER; SURVIVAL;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; ETOPOSIDE; FEMALE; HUMAN; MIDDLE AGE; OVARIAN NEOPLASMS;

EID: 0024549708     PISSN: 02775379     EISSN: None     Source Type: Journal    
DOI: 10.1016/0277-5379(89)90199-5     Document Type: Article

References (23)

1. Platinum salvage therapy in recurrent advanced ovarian carcinoma
2. High dose cisplatin compared with high dose cyclophosphamide in the management of advanced epithelial ovarian cancer (FIGO stages III and IV): report from the North Thames Cooperative Group
3. Combination of bleomycin and mitomycin after failure of cisplatin and alkylating agent therapy in epithelial ovarian cancer
4. High-dose cyclophosphamide therapy for malignant disease
5. High-dose platinum for the treatment of refractory ovarian cancer
6. Use of high-dose cis-platinum (II) following failure on previous chemotherapy for advanced carcinoma of the ovary
7. Effective high-dose chemotherapy with autologous bone marrow infusion in resistant ovarian cancer
8. High-dosage chemotherapy with autologous bone marrow reinfusion in the treatment of patients with solid tumors: the Groningen experience 1981–1986
9. World Health Organization Handbook for Reporting Results of Cancer Treatment
10. Predictive value of Ca 125 antigen levels in second look procedures for ovarian cancer
11. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples
12. Staging system for cancer at gynecologic sites
13. The chemotherapy of ovarian carcinoma
14. Cardiotoxicity associated with high-dose cyclophosphamide therapy
15. Controlled clinical studies with antidote against the urotoxicity of oxazaphosphorines: preliminary results
16. High-dose etoposide for refractory malignancies: a phase I study
17. Review of etoposide single-agent activity
18. A phase II study of etoposide in advanced ovarian cancer with primary or secondary resistance to high dose cisplatin containing regimens
19. Cisplatin plus VP 16-213 in refractory ovarian carcinoma
20. Cisplatin plus etoposide as second-line treatment in advanced ovarian carcinoma
21. Phase II trial of intraperitoneal cisplatin and etoposide in recurrent/refractory ovarian cancer
22. Intensive induction chemotherapy and intensification with autologous bone marrow reinfusion in patients with stage IIIB and IV breast cancer
23. Chemotherapy with maximally tolerable doses of VP 16-213 and cyclophosphamide followed by autologous bone marrow transplantation for the treatment of relapsed or refractory germ cell tumors